EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma

Mengnan Qu, Li Zhou, Xieqiao Yan, Siming Li, Xiaowen Wu, Huayan Xu, Juan Li, Jun Guo, Xu Zhang, Hongzhao Li, Xinan Sheng

Bladder · 01.01.1970 · 10 (1) · 1

DOI: 10.14440/bladder.2023.871 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bladder, online erschienen am 01.01.1970. Verfasst von Mengnan Qu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary oncology, Peking University …. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC) represents a common malignancy of the urinary system that can involve the kidneys, ureter, bladder, and urethra. Advanced/metastatic UC (mUC) tends to have a poor prognosis. UC ranks third in terms of human epidermal growth factor receptor 2 (HER2) overexpression among all tumors. However, multiple studies found that, unlike breast cancer, variable degrees of HER2 positivity and poor consistency between HER2 protein overexpression and gene amplification have been found. Trials involving trastuzumab, pertuzumab, lapatinib, afatinib, and neratinib have failed to prove their beneficial effect in patients with HER2-positive mUC, and a clinical trial on T-DM1 (trastuzumab emtansine) was terminated prematurely because of the adverse reactions. However, a phase II trial showed that RC48-ADC was effective. In this review, we provided an in-depth overview of the advances in the research regarding HER2-targeted therapy and the role of HER2 in mUC. Furthermore, we also discussed the prospects of potential strategies aimed at overcoming anti-HER2 resistance, and summarize the novel anti-HER2 approaches for the management of mUC used in recent clinical trials.

Schlagwörter

Stichwörter der Autor:innen

HER2advanced/metastatic bladder canceradvanced/metastatic urothelial cancertargeted therapy

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Urology, Chinese PLA General Hospital.

Zitieren

APA

Qu, M., Zhou, L., Yan, X., Li, S., Wu, X., Xu, H., Li, J., Guo, J., Zhang, X., Li, H., & Sheng, X. (1970). Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma. Bladder, 10(1), 1. https://doi.org/10.14440/bladder.2023.871

Vancouver

Qu M, Zhou L, Yan X, Li S, Wu X, Xu H, et al. Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma. Bladder. 1970;10(1):1. doi:10.14440/bladder.2023.871

BibTeX
@article{Qu1970,
  author = {Qu, Mengnan and Zhou, Li and Yan, Xieqiao and Li, Siming and Wu, Xiaowen and Xu, Huayan and Li, Juan and Guo, Jun and Zhang, Xu and Li, Hongzhao and Sheng, Xinan},
  title = {Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma},
  journal = {Bladder},
  year = {1970},
  volume = {10},
  number = {1},
  pages = {1},
  doi = {10.14440/bladder.2023.871}
}
Kostenlos starten →